Description
Cerebrolysin is a complex mixture of low-molecular-weight peptides and free amino acids obtained from enzymatic cleavage of porcine brain tissue. This makes cerebrolysin fundamentally different from synthetic single peptides like semax or selank: it is a defined peptide mixture, not a single molecule.
In research literature, cerebrolysin has been studied since the 1970s and is among the oldest continuously researched neuropeptide compounds. The research focus lies on neuroprotection and neuronal plasticity. Mechanistically, cerebrolysin acts in preclinical studies like a cocktail of neurotrophic factors, with documented effects on BDNF signaling, neuronal differentiation and inhibition of apoptotic pathways.
The clinical database is particularly extensive in the area of ischemic stroke and cognitive impairment research. The CARS trials (Cerebrolysin and Recovery After Stroke) are the best-known phase 3 studies that have documented effects on neurological recovery endpoints.
A particularity of cerebrolysin: it is not distributed in 10-vial packs of single vials in research practice, but in 6-pack configurations. This standard has historical reasons and is the established research configuration.
Cerebrolysin is available as lyophilized powder in a 6-pack with 60mg per vial (360mg total). Reconstitute with bacteriostatic water before use (3ml per vial = 20mg/ml).
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Cerebrolysin is considered well tolerated per study reports and is among the longest and most extensively clinically studied neuropeptide compounds.
Observed in research and user reports:
- Injection site: mild redness, warmth or pressure at the injection site is the most common local observation.
- Circulation: clinical studies have occasionally described dizziness, mild headache or a sensation of warmth, particularly with overly rapid administration.
- Porcine origin: cerebrolysin is obtained from porcine brain tissue, a defined peptide mixture rather than a single molecule, which limits batch-to-batch consistency and mechanistic clarity compared to mono-peptides.
- Long-term data: the clinical data base is substantial, but it focuses on defined indications and limited treatment periods.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled Trial - Stroke 2016: Phase 3 trial with 208 participants over 90 days.
- Cerebrolysin in Alzheimer’s disease - Journal of Neural Transmission 2007: Overview of cognitive research endpoints.
- Mechanism of action of Cerebrolysin - Expert Opinion on Investigational Drugs 2005: Mechanism overview of neurotrophic action.
